184 related articles for article (PubMed ID: 36597983)
1. Long-term persistence of second-line biologics in psoriatic arthritis patients with prior TNF inhibitor exposure: a nationwide cohort study from the French health insurance database (SNDS).
Pina Vegas L; Hoisnard L; Bastard L; Sbidian E; Claudepierre P
RMD Open; 2022 Dec; 8(2):. PubMed ID: 36597983
[TBL] [Abstract][Full Text] [Related]
2. Persistence of second-line biologics in psoriasis after first-line biologic failure: a nationwide cohort study from the French health insurance database (SNDS).
Marcombes C; Penso L; Weill A; Dray-Spira R; Zureik M; Sbidian E
Br J Dermatol; 2023 Oct; 189(5):561-568. PubMed ID: 37479503
[TBL] [Abstract][Full Text] [Related]
3. Long-term Persistence of First-line Biologics for Patients With Psoriasis and Psoriatic Arthritis in the French Health Insurance Database.
Pina Vegas L; Penso L; Claudepierre P; Sbidian E
JAMA Dermatol; 2022 May; 158(5):513-522. PubMed ID: 35319735
[TBL] [Abstract][Full Text] [Related]
4. Influence of sex on the persistence of different classes of targeted therapies for psoriatic arthritis: a cohort study of 14 778 patients from the French health insurance database (SNDS).
Pina Vegas L; Penso L; Sbidian E; Claudepierre P
RMD Open; 2023 Dec; 9(4):. PubMed ID: 38114199
[TBL] [Abstract][Full Text] [Related]
5. Treatment Persistence and Adherence Among Patients With Psoriatic Arthritis Who Initiated Targeted Immune Modulators in the US: A Retrospective Cohort Study.
Walsh JA; Cai Q; Lin I; Pericone CD; Chakravarty SD
Adv Ther; 2021 May; 38(5):2353-2364. PubMed ID: 33759081
[TBL] [Abstract][Full Text] [Related]
6. Real-world evaluation of persistence, effectiveness and usage patterns of tofacitinib in treatment of psoriatic arthritis in Australia.
Littlejohn G; Leadbetter J; Butcher BE; Feletar M; O'Sullivan C; Smith T; Witcombe D; Ng HY; Youssef P
Clin Rheumatol; 2024 May; 43(5):1579-1589. PubMed ID: 38459357
[TBL] [Abstract][Full Text] [Related]
7. Persistence rates of abatacept and TNF inhibitors used as first or second biologic DMARDs in the treatment of rheumatoid arthritis: 9 years of experience from the Rhumadata® clinical database and registry.
Choquette D; Bessette L; Alemao E; Haraoui B; Postema R; Raynauld JP; Coupal L
Arthritis Res Ther; 2019 Jun; 21(1):138. PubMed ID: 31171024
[TBL] [Abstract][Full Text] [Related]
8. Evaluating the efficacy of biologics with and without methotrexate in the treatment of psoriatic arthritis: a network meta-analysis.
Mease PJ; Reddy S; Ross S; Lisse JR; Reis P; Griffing K; Sapin C; Vadhariya A; Furst DE
RMD Open; 2024 Jan; 10(1):. PubMed ID: 38296801
[TBL] [Abstract][Full Text] [Related]
9. Persistence and effectiveness of the IL-12/23 pathway inhibitor ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: 1-year results from the real-world PsABio Study.
Gossec L; Siebert S; Bergmans P; de Vlam K; Gremese E; Joven-Ibáñez B; Korotaeva TV; Lavie F; Noël W; Nurmohamed MT; Sfikakis PP; Theander E; Smolen JS
Ann Rheum Dis; 2022 Jun; 81(6):823-830. PubMed ID: 35210262
[TBL] [Abstract][Full Text] [Related]
10. Identifying Predictors of First-Line Subcutaneous TNF-Inhibitor Persistence in Patients with Inflammatory Arthritis: A Decision Tree Analysis by Indication.
Dalén J; Svedbom A; Hernlund E; Olofsson T; Black CM
Adv Ther; 2023 Oct; 40(10):4657-4674. PubMed ID: 37599341
[TBL] [Abstract][Full Text] [Related]
11. Risk of major adverse cardiovascular events in patients initiating biologics/apremilast for psoriatic arthritis: a nationwide cohort study.
Pina Vegas L; Le Corvoisier P; Penso L; Paul M; Sbidian E; Claudepierre P
Rheumatology (Oxford); 2022 Apr; 61(4):1589-1599. PubMed ID: 34244706
[TBL] [Abstract][Full Text] [Related]
12. Tolerability and comparative effectiveness of TNF, IL-17 and IL-23(p19) inhibitors in psoriatic arthritis: a target trial emulation study.
Stisen ZR; Nielsen SM; Skougaard M; Mogensen M; Jørgensen TS; Dreyer L; de Wit M; Christensen R; Kristensen LE
Rheumatology (Oxford); 2024 May; 63(6):1543-1551. PubMed ID: 37713434
[TBL] [Abstract][Full Text] [Related]
13. Prevalence and predictors of tumour necrosis factor inhibitor persistence in psoriatic arthritis.
Stober C; Ye W; Guruparan T; Htut E; Clunie G; Jadon D
Rheumatology (Oxford); 2018 Jan; 57(1):158-163. PubMed ID: 29077973
[TBL] [Abstract][Full Text] [Related]
14. Patient characteristics associated with use of TNF vs interleukin inhibitors as first-line biologic treatment for psoriatic arthritis.
Jin Y; Chen SK; Lee H; Landon JE; Merola JF; Kim SC
J Manag Care Spec Pharm; 2021 Aug; 27(8):1106-1117. PubMed ID: 34337987
[No Abstract] [Full Text] [Related]
15. Long-term effectiveness and persistence of ustekinumab and TNF inhibitors in patients with psoriatic arthritis: final 3-year results from the PsABio real-world study.
Gossec L; Siebert S; Bergmans P; de Vlam K; Gremese E; Joven-Ibáñez B; Korotaeva TV; Lavie F; Noël W; Nurmohamed MT; Sfikakis PP; Sharaf M; Theander E; Smolen JS
Ann Rheum Dis; 2023 Apr; 82(4):496-506. PubMed ID: 36600178
[TBL] [Abstract][Full Text] [Related]
16. Management of Peripheral Arthritis in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations.
Leung YY; Korotaeva TV; Candia L; Pedersen SJ; Bautista Molano W; Ruderman EM; Bisoendial R; Perez-Alamino R; Olsder W; Möller B; Grazio S; Gudu T; Mody GM; Pineda C; Raffayova H; Rohekar S; Goldenstein-Schainberg C; Gutierrez Urena SR; Casasola Vargas JC; Meghnathi B; Prasad R; Richette P; Miranda JRS; Malliotis N; Lindqvist U; Simon D; Ezeonyeji A; Soriano ER; FitzGerald O
J Rheumatol; 2023 Jan; 50(1):119-130. PubMed ID: 36243409
[TBL] [Abstract][Full Text] [Related]
17. Haematological malignancies in patients with psoriatic arthritis overall and treated with TNF inhibitors: a Nordic cohort study.
Cordtz RL; Askling J; Delcoigne B; Smedby KE; Baecklund E; Ballegaard C; Isomäki P; Aaltonen K; Gudbjornsson B; Love TJ; Provan SA; Michelsen B; Sexton J; Dreyer L; Hellgren K
RMD Open; 2022 Dec; 8(2):. PubMed ID: 36564101
[TBL] [Abstract][Full Text] [Related]
18. Are interleukin 17 and interleukin 23 inhibitors associated with malignancies?-Insights from an international population-based study.
Kridin K; Abdelghaffar M; Mruwat N; Ludwig RJ; Thaçi D
J Eur Acad Dermatol Venereol; 2024 Feb; 38(2):315-324. PubMed ID: 37730962
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of IL-12/23 inhibition (ustekinumab) versus tumour necrosis factor inhibition in psoriatic arthritis: observational PsABio study results.
Smolen JS; Siebert S; Korotaeva TV; Selmi C; Bergmans P; Gremese E; Joven-Ibáñez B; Katsifis G; Noël W; Nurmohamed MT; Richette P; Sfikakis PP; de Vlam K; Theander E; Gossec L
Ann Rheum Dis; 2021 Nov; 80(11):1419-1428. PubMed ID: 34162594
[TBL] [Abstract][Full Text] [Related]
20. Discontinuation and switching patterns of tumour necrosis factor inhibitors (TNFis) in TNFi-naive and TNFi-experienced patients with psoriatic arthritis: an observational study from the US-based Corrona registry.
Mease PJ; Karki C; Liu M; Li Y; Gershenson B; Feng H; Hur P; Greenberg JD
RMD Open; 2019; 5(1):e000880. PubMed ID: 31168408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
